AcuCort AB is a Sweden-based pharmaceutical company. The company develops oral films ISICORT, which involve chemical substance glucocorticoid dexamethasone that is used for the treatment of acute allergic reactions, as well as for nausea and vomiting during chemotherapy treatments. AcuCort AB operates mostly in Nordic countries.

Employees

Sector

Drug Retailers

Calendar

08-12 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
10/08/26	SEK 0.6280	+1.95%	12,841
07/08/26	SEK 0.6160	-0.96%	586,875
06/08/26	SEK 0.6220	-0.96%	130,273
05/08/26	SEK 0.6280	-0.63%	165,679
04/08/26	SEK 0.6320	-2.47%	124,124

End-of-day quote SPOTLIGHT STOCK MARKET AB

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote SPOTLIGHT STOCK MARKET AB Other stock markets 10/08/2026			5-day change	1st Jan Change
0.6280 ^SEK	+1.95%		-3.09%	+4.67%

09:20am	Acucort's phase IV study with Zeqmelit published	FW
08-07	Acucort postpones interim report to August 19	FW

Market Cap	147M 15.48M 13.41M 12.56M 11.46M 21.56M 1.48B 21.92M 57.69M 739M 58.11M 56.85M 2.47B	P/E 2024	-3.61x	P/E 2025	-5x
Enterprise Value	120M 12.64M 10.95M 10.25M 9.36M 17.6M 1.21B 17.9M 47.1M 603M 47.45M 46.42M 2.01B	EV / Sales 2024	11.3x	EV / Sales 2025	17x
Free-Float	36.58%	Yield 2024 *	-	Yield 2025	-

09:20am	Acucort's phase IV study with Zeqmelit published	FW
08-07	Acucort postpones interim report to August 19	FW
07-27	AcuCort Receives Renewed FDA Small Business Waiver Ahead of Planned NDA Submission	CI
07-27	AcuCort Renews US FDA Small Business Waiver for New Drug Applications	MT
07-27	FDA waives application fee for Acucort	FW
06-11	Acucort sees increased partner interest ahead of BIO Convention in the U.S.	FW
05-27	AcuCort CEO: Focus on strengthening presence in existing markets, developing new partnerships, and advancing in the US	FW
04-28	Acucort reports slight increase in operating loss	FW
04-28	AcuCort AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	AcuCort and the FDA Agree on iPSP - Important Step Towards US Market Approval	CI
04-13	AcuCort Makes Progress in US Regulatory Process for Zeqmelit	MT
04-13	Acucort plans to apply for U.S. market approval for Zeqmelit in 2026	RE
04-13	Acucort reaches milestone for US approval of Zeqmelit	FW

09:21am	AcuCort : first Phase IV study is now published	PU
09:15am	AcuCort: AcuCort’s first Phase IV study is now published	PU
09:13am	AcuCort's first Phase IV study is now published	AQ
07-27	AcuCort : granted renewed FDA Small Business Waiver – Important milestone ahead of planned NDA submission in 2026	PU
07-27	AcuCort: AcuCort granted renewed FDA Small Business Waiver – Important milestone ahead of planned NDA submission in 2026	PU

AcuCort AB Share Price

Stocks

ACUC

SE0009695927

Drug Retailers

Valuation: AcuCort AB

Chart: AcuCort AB

Latest news : AcuCort AB

Press Releases: AcuCort AB

Quotes and Performance

Course Extremes

Managers and Directors: AcuCort AB

Other Drug Retailers

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+1.95%
1 week	-3.09%
Current month	-3.09%
1 month	-1.88%
3 months	-9.51%
6 months	-29.75%
Current year	+4.67%

1 week	0.56	0.65
1 month	0.53	0.66
Current year	0.4	0.95
1 year	0.4	0.95
3 years	0.33	1.26
5 years	0.33	4.98
10 years	0.33	9.5

Manager	Title	Age	Since
Jonas Jonas Jönmark CEO	Chief Executive Officer	55	08/08/2020
Anna Cherouvrier Hansson PRN	Corporate Officer/Principal	53	13/10/2025

Director	Title	Age	Since
Anna Maria Albertina Eriksrud BRD	Director/Board Member	68	07/02/2017
Ebba Cecilia Fåhraeus CHM	Chairman	63	31/12/2017
Göran Tornling BRD	Director/Board Member	79	31/12/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACUCORT AB	+1.95%	-3.09%	-7.37%	-43.42%	15.52M
JD HEALTH INTERNATIONAL INC.	-1.60%	-0.90%	-25.30%	-25.16%	16.29B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-0.96%	+0.28%	-26.47%	-35.50%	7.54B
MATSUKIYOCOCOKARA & CO.	+2.69%	+2.44%	-24.12%	-11.95%	6.33B
YIFENG PHARMACY CHAIN CO., LTD.	+5.16%	+8.50%	+2.97%	-24.11%	4.21B
NAHDI MEDICAL COMPANY	-0.05%	+0.26%	-22.06%	-37.50%	3.33B
CLICKS GROUP LIMITED	-1.19%	-1.37%	-41.84%	-24.97%	3.13B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	+3.46%	+1.95%	+7.22%	-33.71%	3.08B
GUARDIAN PHARMACY SERVICES, INC.	-4.65%	-2.54%	+98.69%	-	2.63B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	-0.07%	-1.65%	-14.71%	+3.22%	2.62B
Average	+0.47%	+265.74%	-5.30%	-25.90%	4.92B
Weighted average by Cap.	-0.00%	+340.75%	-14.51%	-24.79%

	2024	2025
Net sales	7.72M 811K 703K 658K 601K 1.13M 77.37M 1.15M 3.02M 38.73M 3.05M 2.98M 129M	6.68M 703K 609K 570K 520K 979K 67.01M 995K 2.62M 33.54M 2.64M 2.58M 112M
Net income	-17.4M -1.83M -1.58M -1.48M -1.35M -2.55M -174M -2.59M -6.82M -87.31M -6.87M -6.72M -291M	-26.19M -2.75M -2.39M -2.23M -2.04M -3.84M -263M -3.9M -10.26M -131M -10.34M -10.11M -438M
Net Debt	-2.77M -291K -253K -236K -216K -406K -27.79M -413K -1.09M -13.91M -1.09M -1.07M -46.41M	-27.01M -2.84M -2.46M -2.3M -2.1M -3.96M -271M -4.02M -10.58M -136M -10.66M -10.43M -452M